NaV1.7 as a pain target - From gene to pharmacology

NaV1.7, a subtype of the voltage-gated sodium channel family that is highly expressed in peripheral sensory neurons, remains one of the most promising targets for the treatment of pain. However, despite compelling genetic evidence supporting a key role for NaV1.7 in regulating excitability of peripheral sensory neurons, the development of truly subtype-selective inhibitors has been challenging. Here, we discuss complexities surrounding targeting NaV1.7 pharmacologically for treatment of pain and explore future opportunities for development of effective analgesic NaV1.7 inhibitors.